T1	Participants 357 378	total of 210 patients
T2	Participants 797 915	204 patients evaluable for response assessment, the response rates were 48.6% for GP1, 52.2% for GP2, and 52.3% for GD
T3	Participants 1108 1141	208 patients evaluable for safety
